Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook
Eledon Pharmaceuticals, Inc. (ELDN)
Company Research
Source: GlobeNewswire
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Completed two financings totaling $135 million in combined gross proceeds, with funds expected to support operations through end of 2026 IRVINE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced a summary of 2024 accomplishments and provided guidance for anticipated 2025 business milestones. “2024 was a transformative yea
Show less
Read more
Impact Snapshot
Event Time:
ELDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELDN alerts
High impacting Eledon Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ELDN
News
- Eledon Pharmaceuticals (NASDAQ:ELDN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare ConferenceGlobeNewswire
- Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineGlobeNewswire
- Eledon Pharmaceuticals (NASDAQ:ELDN) had its price target lowered by analysts at Guggenheim from $9.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
ELDN
Earnings
- 11/14/25 - Beat
ELDN
Sec Filings
- 11/24/25 - Form SCHEDULE
- 11/14/25 - Form 8-K
- 11/14/25 - Form 10-Q
- ELDN's page on the SEC website